Hyperglycemia
Dipeptidyl Peptidase-4
Treatment Algorithm
Overview of Pharmacologic Therapy
Acute Complications
Oral Agents
Q&A: CGM ‘revolutionary’ for pregnant women with diabetes
Continuous glucose monitors have the potential to alleviate burdens, improve neonatal outcomes and predict disease progression for pregnant women with type 1, type 2 or gestational diabetes, according to two diabetes experts.
Relacorilant tied to sustained cardiometabolic improvements in Cushing’s syndrome
PHILADELPHIA — Adults with Cushing’s syndrome who responded to relacorilant had sustained improvements in blood pressure and glucose levels through 34 weeks, according to findings from a phase 3 trial.
AI, new technology major focus at 2024 AACE annual meeting
Looking to the future will be a key theme at the American Association of Clinical Endocrinology 2024 annual meeting with a keynote lecture focused on AI and sessions examining guidance updates and new technology.
Investigational Cushing’s syndrome medication reduces BP, glucose in open-label trial
Adults with endogenous Cushing’s syndrome had reductions in blood pressure and glucose at 22 weeks of treatment with a selective cortisol modulator, according to topline results from the open-label portion of the GRACE phase 3 trial.
BLOG: My colleague experienced real-life consequence of daylight savings time change
This year is the first that I did not write a post on the weekend of the biannual daylight savings time change since the launch of this blog. In each earlier post, I aimed to raise awareness about health risks due to the time change.